12:00 AM
 | 
Jan 12, 2009
 |  BC Week In Review  |  Company News  |  Deals

ExonHit, Allergan deal

The partners extended by two years a 2003 deal to use ExonHit's DATAS gene profiling technology to identify targets in neurodegenerative diseases, pain and ophthalmology. This is...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >